http://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here
 

 

 

Latest News !
 

 

Federal Election 2016: Promises, Evidence And Credibility
- Jun 30, 2016

Teva Returns Mesoblast Heart Drug; Equity Facility - Jun 14, 2016

Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

Budget 2016: Not Much For Biotech, Innovation
- Details, Comment - May 3, 4, 2016

NHMRC $3.3m For Windfarm Health Impacts
AMA Position, Biotech Daily Comment - Mar 22, 2016

2015 - The Year In Review

PM Malcolm Turbull Launches $1.1b Innovation, Science Agenda
Comment - Dec 7, 8, 2015

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization

 

10-Year BDI-40 Up 163%, ASX200 Up 3%
Big Caps Up 308%, NBI Up 262%

Year-To-June 30: BDI-40 Up 8%, ASX200 Down 4%, Big Caps Up 27%

 

 
July 1, 2016
 
They say that biotechnological development moves at a glacial pace and today’s data proves that this sector is more for decade-traders than day-traders.
 
The Biotech Daily Top 40 Index (BDI-40) - which does not include the three Big Caps of Cochlear, CSL and Resmed - is 10 years old today and it is up 163.4 percent compared to June 30, 2006.

The ASX200 has improved just 3.1 percent in 10 years, with the Big Caps up a collective 307.5 percent from $17,156 million on June 30, 2006 to $69,910 million last night.
 
The Nasdaq Biotech Index (NBI) climbed 262.4 percent in the decade.
 
For the year to June 30, 2016, the BDI-40 was up a respectable 8.4 percent, the ASX200 fell 4.1 percent, the NBI lost 30.3 percent, but the Big Caps improved 27.1 percent, but the month of June was bad for everyone, with the BDI-40 down 11.1 percent, the ASX200 down 2.7 percent and even the Big Caps retreated 1.9 percent.
 
The June BDI-40 saw many small falls and a few small rises, but Teva returning Mesoblast’s cardiac program wiped $343 million from the Index, and along with Sirtex easing $340 million, accounting for most of the loss.
 
For the month to June 30, 2016, 27 of the BDI-40 companies fell, 10 were up and three were unchanged.
 
Living Cell was the best, up 37.0 percent to $37 million followed by Uscom (28.6%), Airxpanders (25.1%), Cellmid (24.0%), Prana (20.5%) and Universal Biosensors (14.3%).
 
Mesoblast led the falls, down 45.6 percent to $410 million, followed by Antisense (28.6%), Orthocell (24.0%), IDT (23.4%), Psivida (21.0%), Actinogen (20.0%) and Sirtex (18.8%).
 
Cochlear was up $33 million to $6,936 million, CSL eased 1.2 percent from last month’s high to $51,323 million and Resmed edged up 2.2 percent to $11,651 million.
 
The Nasdaq Biotech Index fell 7.9 percent in June, with former Australian companies Heartware up 90.9 percent to $1,359, Aviragen (Biota) down 7.6 percent to $73 million and Sunshine Heart losing 33 percent to a low of $12 million.
 
Outside the BDI-40, Cyclopharm, Innate, OBJ and Resapp continued to improve, while generics manufacturer Mayne Pharma jumped 19.8 percent to $1,543 million.
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Jun 30, 2016 – Adjusted
 
 
BDI-40 v S&P ASX200 Jun 30, 2015 to Jun 30, 2016 
 
 
 
Big Caps (Cochlear, CSL, Resmed) Jun 30, 2015 to Jun 30, 2016
 
 
 

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At June 30, 2016

 

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in